Trials / Terminated
TerminatedNCT05780736
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
Conditions
Timeline
- Start date
- 2023-08-04
- Primary completion
- 2024-08-23
- Completion
- 2024-08-23
- First posted
- 2023-03-23
- Last updated
- 2024-09-25
Locations
24 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT05780736. Inclusion in this directory is not an endorsement.